CompoAtlas

Valdispert gommes Cannabis sativa

Food supplement declared in France, declaration No 2021-7-1276, decision dated 26 July 2021

Valdispert gommes Cannabis sativa, from VEMEDIA CONSUMER HEALTH FRANCE, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Passiflora incarnata 150 mg per day, Cannabis sativa 130 mg per day. 1 point in its composition requires a check (prohibited substance, dose or novel food).

Brand
Valdispert
Food business operator placing the product on the market
VEMEDIA CONSUMER HEALTH FRANCE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Chewing gum
Daily dose
2
Directions for use
2 gommes par jour
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Nervous system

Declaration 305686, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Passiflora incarnata L.FleurExtrait sec aqueux150 mg
Cannabis sativa L.Graine (huile)Pression à froid130 mg

Additives

E330, E903, E440

Other ingredients

sirop de glucose, sucre, Eau purifiée, huile végétale

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Reservé aux adultes. L’utilisation n’est pas recommandée aux femmes enceintes et allaitantes. Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des enfants. A conserver dans un endroit sec et à température inférieure à 25 C Complément alimentaire ne remplaçant pas une alimentation saine et variée ainsi qu’un mode de vie sain.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Passiflora incarnata L.
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Valdispert

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Valdispert gommes Cannabis sativa: composition and regulation”, https://compoatlas.com/en/supplements/products/305686-valdispert-gommes-cannabis-sativa, updated 15 November 2026.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line